Assessment of Response to Therapy for Bone Metastases: Is it Still a Challenge in Oncology?

被引：3
作者：
Collignon, J. [1 ]
Gennigens, C. [1 ]
Jerusalem, G. [1 ,2 ]
机构：
[1] CHU Sart Tilman Liege, Div Med Oncol, Domaine Univ,B35, Liege, Belgium
[2] Univ Liege, B-4000 Liege, Belgium
来源：
PET CLINICS | 2010年 / 5卷 / 03期
关键词：
Bone metastasis; Response assessment; Breast cancer; Prostate cancer; Diagnostic imaging; FDG-PET;
D O I：
10.1016/j.cpet.2010.05.002
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Bone is one of the most common sites of metastases from cancer. Most anticancer treatments are highly toxic but only a fraction of all patients respond to them. Guidelines are needed to evaluate the response in the routine practice of oncology as well as in clinical trials in which new treatment options are evaluated. All current imaging procedures have major limitations. This article reviews old and new criteria for response evaluation. The major problem of accurate response evaluation in bone disease is discussed in detail. Some examples from our daily practice illustrate the difficulties. The indications for bone biopsy are also reviewed. © 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码：311 / 326
页数：16
相关论文
共 42 条
  • [1] Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis
    Baeuerle, Tobias
    Bartling, Soenke
    Berger, Martin
    Schmitt-Graeff, Annette
    Hilbig, Heidegard
    Kauczor, Hans-Ulrich
    Delorme, Stefan
    Kiessling, Fabian
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2010, 73 (02) : 280 - 287
  • [2] Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases
    Beheshti, Mohsen
    Langsteger, Werner
    Fogelman, Ignac
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2009, 39 (06) : 396 - 407
  • [3] Berstein L, 2002, EUR J OBSTET GYN R B, V105, P161
  • [4] Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma
    Blomqvist, C
    Risteli, L
    Risteli, J
    Virkkunen, P
    Sarna, S
    Elomaa, I
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (09) : 1074 - 1079
  • [5] Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: An update review
    Bouchelouche, Kirsten
    Oehr, Peter
    [J]. JOURNAL OF UROLOGY, 2008, 179 (01) : 34 - 45
  • [6] Correlation Between Pretreatment Serum Biochemical Markers and Treatment Outcome for Prostatic Cancer with Bony Metastasis
    Chen, Shiou-Sheng
    Chen, Kuang-Kuo
    Lin, Alex T. L.
    Chang, Yen-Hwa
    Wu, Howard H. H.
    Chang, Luke S.
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2009, 72 (06) : 301 - 306
  • [7] Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference
    Coleman, Robert E.
    Guise, Theresa A.
    Lipton, Allan
    Roodman, G. David
    Berenson, James R.
    Body, Jean-Jacques
    Boyce, Brendan F.
    Calvi, Laura M.
    Hadji, Peyman
    McCloskey, Eugene V.
    Saad, Fred
    Smith, Matthew R.
    Suva, Larry J.
    Taichman, Russell S.
    Vessella, Robert L.
    Weilbaecher, Katherine N.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6387 - 6395
  • [8] COOMBES RC, 1983, CANCER, V52, P610, DOI 10.1002/1097-0142(19830815)52:4<610::AID-CNCR2820520406>3.0.CO
  • [9] 2-5
  • [10] Sequential positron emission tomography using [18F] fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer
    Couturier, Olivier
    Jerusalem, Guy
    N'Guyen, Jean-Michel
    Hustinx, Roland
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (21) : 6437 - 6443
12345